story of the week
Neoadjuvant Immune Checkpoint Blockade for Retroperitoneal Dedifferentiated Liposarcoma and Extremity/Truncal Undifferentiated Pleomorphic Sarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma
Nat Cancer 2024 Feb 13;[EPub Ahead of Print], CL Roland, EF Nassif Haddad, EZ Keung, WL Wang, AJ Lazar, H Lin, M Chelvanambi, ER Parra, K Wani, BA Guadagnolo, AJ Bishop, EM Burton, KK Hunt, KE Torres, BW Feig, CP Scally, VO Lewis, JE Bird, R Ratan, D Araujo, MA Zarzour, S Patel, R Benjamin, AP Conley, JA Livingston, V Ravi, HA Tawbi, PP Lin, BS Moon, RL Satcher, B Mujtaba, RG Witt, RS Traweek, B Cope, R Lazcano, CC Wu, X Zhou, MM Mohammad, RA Chu, J Zhang, A Damania, P Sahasrabhojane, T Tate, K Callahan, S Nguyen, D Ingram, R Morey, S Crosby, G Mathew, S Duncan, CF Lima, JY Blay, WH Fridman, K Shaw, I Wistuba, A Futreal, N Ajami, JA Wargo, N SomaiahFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.